- Home
- INAB vs ABP Comparison
INAB vs ABP Comparison
Compare INAB & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- ABP
- Stock Information
- Founded
- INAB 2016
- ABP 2004
- Country
- INAB United States
- ABP United States
- Employees
- INAB N/A
- ABP N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- ABP Health Care
- Exchange
- INAB Nasdaq
- ABP Nasdaq
- Market Cap
- INAB 14.5M
- ABP 15.5M
- IPO Year
- INAB 2021
- ABP N/A
- Fundamental
- Price
- INAB $2.17
- ABP $0.21
- Analyst Decision
- INAB Strong Buy
- ABP Strong Buy
- Analyst Count
- INAB 2
- ABP 1
- Target Price
- INAB $108.00
- ABP $4.00
- AVG Volume (30 Days)
- INAB 383.7K
- ABP 5.6M
- Earning Date
- INAB 08-07-2025
- ABP 08-18-2025
- Dividend Yield
- INAB N/A
- ABP N/A
- EPS Growth
- INAB N/A
- ABP N/A
- EPS
- INAB N/A
- ABP N/A
- Revenue
- INAB N/A
- ABP $183,000.00
- Revenue This Year
- INAB N/A
- ABP N/A
- Revenue Next Year
- INAB N/A
- ABP N/A
- P/E Ratio
- INAB N/A
- ABP N/A
- Revenue Growth
- INAB N/A
- ABP 88.66
- 52 Week Low
- INAB $2.06
- ABP $0.15
- 52 Week High
- INAB $27.60
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- INAB 27.49
- ABP N/A
- Support Level
- INAB $2.06
- ABP N/A
- Resistance Level
- INAB $2.31
- ABP N/A
- Average True Range (ATR)
- INAB 0.31
- ABP 0.00
- MACD
- INAB -0.00
- ABP 0.00
- Stochastic Oscillator
- INAB 4.74
- ABP 0.00
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.